IMF Videos Search Content For Healthcare Professional (96) Healthcare Provider (96) Series - Any - About the IMF (2) ASCO/EHA (71) ASH (102) Ask Dr. Durie (149) Black Swan Research Initiative (7) Community Workshops (5) Emerging Therapies (18) Facebook Live (21) Health Equity (14) IMF History (3) IMWG (12) Inspirational (15) Living Well with Myeloma (33) Myeloma in a Minute (25) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (11) Q&A (22) Recent News and Developments (5) Treatments (3) Trending Searches in Myeloma (4) Topics Clinical Trials (60) Financial Considerations (1) Frontline Therapy (10) Health Equity (8) Inspirational Stories (1) Lab & Imaging Tests (14) Recorded Webinars (1) Relapse/Refractory Myeloma (30) Research Updates (69) Symptom Management (4) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (15) High-Risk Myeloma (12) High-risk Smoldering Myeloma (7) Late Relapse (4–6 Lines of Therapy) (25) MGUS (16) Newly Diagnosed (Pre-Treatment or First Treatment) (19) Smoldering Myeloma (15) Types of Therapy Immunomodulatory drugs (IMiDs) (18) Immunotherapies (CAR T; BiTE, etc.) (27) Monoclonal antibodies (12) Proteasome inhibitors (14) Stem cell transplant (13) Steroids (10) Supportive Care (8) Year Published 2026 (7) 2025 (23) 2024 (22) 2023 (19) 2022 (13) 2021 (7) 2020 (1) 2019 (8) 2018 (1) 2016 (1) Trusted Voices Dr. María-Victoria Mateos (6) Dr. Shaji Kumar (2) Dr. Joseph Mikhael (1) Dr. Saad Usmani (1) Dr. Sigurður Kristinsson (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Ultra-Sensitive Assessment of MRD in Peripheral Blood of Multiple Myeloma Patients Using Bloodflow December 26, 2022 ASH Autoimmune Diseases Are Not Associated with MGUS: Results of the Population-Based iStopMM December 23, 2022 ASH Hypercalcemia in Individuals with MGUS: Results from the iStopMM Study December 23, 2022 ASH Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T-cell Therapy December 23, 2022 ASH Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma: Post-Hoc Analysis of Sustained Undetectable MRD December 22, 2022 ASH Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: iStopMM Study December 21, 2022 ASH The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma December 21, 2022 ASH Does SARS-CoV-2 Vaccination Impact the Risk of Progression from MGUS to MM? December 16, 2022 ASH Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The iStopMM Study December 15, 2022 ASH MRD2STOP: Can multimodal MRD negativity guide discontinuation of maintenance treatment in myeloma? December 13, 2022 ASH Updates on the Binding Site's ongoing collaboration with the iStopMM study January 27, 2022 ASH Screening for Monoclonal Gammopathy of Undetermined Significance: First Results from the iStopMM Study January 26, 2022 ASH Load More
